dc.contributor.author | Weidenbacher, Payton A.-B. | |
dc.contributor.author | Sanyal, Mrinmoy | |
dc.contributor.author | Friedland, Natalia | |
dc.contributor.author | Tang, Shaogeng | |
dc.contributor.author | Arunachalam, Prabhu S. | |
dc.contributor.author | Hu, Mengyun | |
dc.contributor.author | Kumru, Ozan S. | |
dc.contributor.author | Morris, Mary Kate | |
dc.contributor.author | Fontenot, Jane | |
dc.contributor.author | Shirreff, Lisa | |
dc.contributor.author | Do, Jonathan | |
dc.contributor.author | Cheng, Ya-Chen | |
dc.contributor.author | Vasudevan, Gayathri | |
dc.contributor.author | Feinberg, Mark B. | |
dc.contributor.author | Villinger, Francois J. | |
dc.contributor.author | Hanson, Carl | |
dc.contributor.author | Joshi, Sangeeta B. | |
dc.contributor.author | Volkin, David B. | |
dc.contributor.author | Pulendra, Bali | |
dc.contributor.author | Kim, Peter S. | |
dc.date.accessioned | 2023-05-30T19:40:23Z | |
dc.date.available | 2023-05-30T19:40:23Z | |
dc.date.issued | 2023-04-17 | |
dc.identifier.citation | Weidenbacher, P.AB., Sanyal, M., Friedland, N. et al. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nat Commun 14, 2149 (2023). https://doi.org/10.1038/s41467-023-37417-9 | en_US |
dc.identifier.uri | https://hdl.handle.net/1808/34235 | |
dc.description.abstract | While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ~one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly (or less frequent) booster vaccine, and as a primary vaccine for pediatric use including in infants. | en_US |
dc.publisher | Nature Research | en_US |
dc.rights | © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Antibodies | en_US |
dc.subject | Protein vaccines | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.title | A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Kumru, Ozan S. | |
kusw.kuauthor | Joshi, Sangeeta B. | |
kusw.kuauthor | Volkin, David B. | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
dc.identifier.doi | 10.1038/s41467-023-37417-9 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-7692-0458 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-1365-4279 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0003-0090-5689 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0003-4495-7501 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-5010-7223 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-8403-451X | en_US |
dc.identifier.orcid | https://orcid.org/0000-0001-6517-4333 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0001-6503-4541 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC10110616 | en_US |
dc.rights.accessrights | openAccess | en_US |